Enanta Pharmaceuticals Q1 revenue beats estimates

Enanta Pharmaceuticals

09/02/2026 21:09

Overview

Biotechnology firm's fiscal Q1 revenue rose, beating analyst expectations

Net loss for fiscal Q1 narrowed compared to the previous year

Outlook

Enanta anticipates cash resources to fund operations into fiscal 2029

Result Drivers

ROYALTY REVENUE - Revenue increase attributed to higher sales of AbbVie's MAVYRET/MAVIRET, boosting royalty income

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$18.62 mln
$16.14 mln (4 Analysts)
Q1 EPS
-$0.42
Q1 Net Income
-$11.94 mln
Q1 Operating Expenses
$29.87 mln
Q1 Operating Income
-$11.25 mln
Q1 Pretax Profit
-$11.91 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 48% above its February 6 closing price of $13.51

Press Release: ID:nBw7WR173a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)